Evolve Biologics to break ground for new manufacturing facility in Texas
The facility will be the first to use Evolve’s innovative PlasmaCap EBA technology to produce plasma-derived therapeutics
Evolve Biologics has announced plans to build its first manufacturing facility in Sachse, Texas which will use the company's proprietary technology, PlasmaCap EBA, to commercially produce plasma-derived therapeutics.
According to Jim Caggiano, Evolve's CEO, the next-generation technology is "poised to revolutionise the plasma-derived therapeutics industry" by harvesting significantly higher yields of these proteins from human plasma through a cleaner, more efficient process, compared with existing fractionation technologies.
The technology uses proprietary affinity adsorbents in expanded bed adsorption (EBA) chromatography to capture plasma proteins directly from plasma or fractionated plasma materials without using precipitating solvents such as ethanol.
The new 200,000-sq. ft commercial facility, which will be the foundation of the company's future growth and global strategy, will have production capacity to process one million liters of plasma annually, with a planned expansion to 2 million liters.
As Evolve is currently in the process of commercialising an innovative portfolio of product candidates, the facility will initially produce intravenous immunoglobulin (IVIG) and human serum albumin (HSA).
The company has said it expects to hire approximately 300 new employees to work in the facility during the next 3 years.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance